PL2155717T3 - 2-[4-(PIRAZOL-4-ILOALKILO)PIPERAZYN-1-YLO]-3-FENYLO PIRAZYNY I PIRYDYNY I 3-[4-(PIRAZOL-4-ILOALKILO)PIPERAZYN-1-YLO]-2-FENYLO PIRYDYNY JAKO ANTAGONIŚĆI RECEPTORA 5-HT<sub>7</sub> - Google Patents

2-[4-(PIRAZOL-4-ILOALKILO)PIPERAZYN-1-YLO]-3-FENYLO PIRAZYNY I PIRYDYNY I 3-[4-(PIRAZOL-4-ILOALKILO)PIPERAZYN-1-YLO]-2-FENYLO PIRYDYNY JAKO ANTAGONIŚĆI RECEPTORA 5-HT<sub>7</sub>

Info

Publication number
PL2155717T3
PL2155717T3 PL08747748T PL08747748T PL2155717T3 PL 2155717 T3 PL2155717 T3 PL 2155717T3 PL 08747748 T PL08747748 T PL 08747748T PL 08747748 T PL08747748 T PL 08747748T PL 2155717 T3 PL2155717 T3 PL 2155717T3
Authority
PL
Poland
Prior art keywords
ylalkyl
piperazin
pyrazol
pyridines
phenyl
Prior art date
Application number
PL08747748T
Other languages
English (en)
Polish (pl)
Inventor
Valentina O Badescu
Anne Marie Camp
Barry Peter Clark
Michael Philip Cohen
Sandra Ann Filla
Peter Thaddeus Gallagher
Sarah Lynne Hellman
Michael Philip Mazanetz
Marta Maria Pineiro-Nunez
John Mehnert Schaus
Patrick Gianpietro Spinazze
Maria Ann Whatton
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL2155717T3 publication Critical patent/PL2155717T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL08747748T 2007-05-11 2008-05-07 2-[4-(PIRAZOL-4-ILOALKILO)PIPERAZYN-1-YLO]-3-FENYLO PIRAZYNY I PIRYDYNY I 3-[4-(PIRAZOL-4-ILOALKILO)PIPERAZYN-1-YLO]-2-FENYLO PIRYDYNY JAKO ANTAGONIŚĆI RECEPTORA 5-HT<sub>7</sub> PL2155717T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US91743107P 2007-05-11 2007-05-11
US97420907P 2007-09-21 2007-09-21
PCT/US2008/062834 WO2008141020A1 (en) 2007-05-11 2008-05-07 2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl pyrazines and pyridines and 3-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-2-phenyl pyridines as 5-ht7 receptor antagonists
EP08747748A EP2155717B1 (en) 2007-05-11 2008-05-07 2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl pyrazines and pyridines and 3-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-2-phenyl pyridines as 5-ht7 receptor antagonists

Publications (1)

Publication Number Publication Date
PL2155717T3 true PL2155717T3 (pl) 2013-03-29

Family

ID=39629131

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08747748T PL2155717T3 (pl) 2007-05-11 2008-05-07 2-[4-(PIRAZOL-4-ILOALKILO)PIPERAZYN-1-YLO]-3-FENYLO PIRAZYNY I PIRYDYNY I 3-[4-(PIRAZOL-4-ILOALKILO)PIPERAZYN-1-YLO]-2-FENYLO PIRYDYNY JAKO ANTAGONIŚĆI RECEPTORA 5-HT<sub>7</sub>

Country Status (17)

Country Link
US (1) US8202873B2 (OSRAM)
EP (1) EP2155717B1 (OSRAM)
JP (1) JP5210375B2 (OSRAM)
KR (1) KR101119294B1 (OSRAM)
CN (1) CN101861312B (OSRAM)
AU (1) AU2008251584B2 (OSRAM)
BR (1) BRPI0811446A2 (OSRAM)
CA (1) CA2684563C (OSRAM)
CY (1) CY1113457T1 (OSRAM)
DK (1) DK2155717T3 (OSRAM)
EA (1) EA016529B1 (OSRAM)
ES (1) ES2395872T3 (OSRAM)
HR (1) HRP20120919T1 (OSRAM)
MX (1) MX2009012126A (OSRAM)
PL (1) PL2155717T3 (OSRAM)
PT (1) PT2155717E (OSRAM)
WO (1) WO2008141020A1 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2474581C2 (ru) * 2007-12-26 2013-02-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Способ получения замещенных гетероциклом производных пиридина
WO2011012620A2 (en) * 2009-07-31 2011-02-03 Syngenta Participations Ag Processes for the alkylation of pyrazoles
EP2502909A4 (en) 2009-11-18 2013-04-03 Takeda Pharmaceutical aminopyridine derivative
EP2566333A4 (en) 2010-05-07 2014-04-02 Univ Leland Stanford Junior IDENTIFICATION OF STABILIZERS OF MULTIMEDER PROTEINS
JP5869570B2 (ja) * 2010-08-10 2016-02-24 シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト 3−ハロアルキルピラゾールの調製方法
US10351535B2 (en) * 2013-12-20 2019-07-16 Esteve Pharmaceuticals, S.A. Piperazine derivatives having multimodal activity against pain
EP3179857B1 (en) 2014-08-14 2021-09-08 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
CN104592199A (zh) * 2015-01-22 2015-05-06 杭州利巴医药科技有限公司 一种取代的1-(2-吡啶基)-吡唑-4-基乙酸及其衍生物和制备方法
CN104945325B (zh) * 2015-06-19 2017-04-05 浙江永太科技股份有限公司 一种吡唑甲酸衍生物的制备方法
NZ797281A (en) 2017-02-17 2025-10-31 Eidos Therapeutics Inc Processes for preparing ag-10, its intermediates, and salts thereof
KR20200135996A (ko) 2018-03-23 2020-12-04 에이도스 테라퓨틱스, 인코포레이티드 Ag10을 사용하여 ttr 아밀로이드증을 치료하는 방법
EP4647068A2 (en) 2018-08-17 2025-11-12 Eidos Therapeutics, Inc. Formulations of ag10
KR102514860B1 (ko) * 2020-12-01 2023-03-29 한국과학기술연구원 5-ht7 세로토닌 수용체 활성 저해용 바이페닐 피롤리딘 및 바이페닐 다이하이드로이미다졸 유도체 및 이를 유효성분으로 포함하는 약학 조성물
CN115974785A (zh) * 2022-12-09 2023-04-18 南京先进生物材料与过程装备研究院有限公司 一种3,5-二取代吡唑类化合物的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2079323B1 (es) * 1994-06-21 1996-10-16 Vita Invest Sa Derivados de indol utiles para el tratamiento de la migraña, composicion y uso correspondientes.
EP1676844A1 (en) * 2004-12-28 2006-07-05 Laboratorios Del Dr. Esteve, S.A. 5-HT7 receptor antagonists
MXPA05008137A (es) * 2003-01-31 2005-09-30 Pfizer Prod Inc Antagonistas y agonistas de 5ht7.
US20050080076A1 (en) * 2003-10-08 2005-04-14 Xanodyne Pharmacal, Inc. N-desmethyl levomepromazine

Also Published As

Publication number Publication date
KR20090127436A (ko) 2009-12-11
EA016529B1 (ru) 2012-05-30
US20100120785A1 (en) 2010-05-13
JP5210375B2 (ja) 2013-06-12
MX2009012126A (es) 2009-11-23
WO2008141020A1 (en) 2008-11-20
KR101119294B1 (ko) 2012-04-12
EA200971052A1 (ru) 2010-04-30
CY1113457T1 (el) 2016-06-22
AU2008251584B2 (en) 2013-04-11
HRP20120919T1 (hr) 2012-12-31
JP2010526819A (ja) 2010-08-05
ES2395872T3 (es) 2013-02-15
CN101861312B (zh) 2014-09-03
CA2684563C (en) 2013-08-13
PT2155717E (pt) 2012-12-21
BRPI0811446A2 (pt) 2014-10-29
AU2008251584A1 (en) 2008-11-20
CA2684563A1 (en) 2008-11-20
US8202873B2 (en) 2012-06-19
EP2155717B1 (en) 2012-10-24
DK2155717T3 (da) 2012-11-19
EP2155717A1 (en) 2010-02-24
CN101861312A (zh) 2010-10-13

Similar Documents

Publication Publication Date Title
PL2155717T3 (pl) 2-[4-(PIRAZOL-4-ILOALKILO)PIPERAZYN-1-YLO]-3-FENYLO PIRAZYNY I PIRYDYNY I 3-[4-(PIRAZOL-4-ILOALKILO)PIPERAZYN-1-YLO]-2-FENYLO PIRYDYNY JAKO ANTAGONIŚĆI RECEPTORA 5-HT&lt;sub&gt;7&lt;/sub&gt;
IL216132A (en) Heterocyclic carboxamide diamine compounds, their uses and their medicinal products and inhibitors
SG10201402492TA (en) Use of jak inhibitors 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile
PT2001849E (pt) Derivados de piridina e pirimidina como antagonistas de r2mglu
GB0722203D0 (en) Use of CRTH2 antagonist compounds
IL215362A0 (en) Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
PL2188268T3 (pl) Podstawione piperazynylopirazyny i -pirydyny jako antagoniści receptora 5-HT7
IL223543A (en) Pharmaceutical preparation containing 1– (4– (4– (4,3-dichloro-2 – fluorophenylamino) –7 – methoxyquinazoline – 6 – Iloxy) piperidine – 1 – il) Prof. 2 – an – 1 – on or a common pharmaceutical salt His and an acidic addition
ZA201201360B (en) New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
IL200780A0 (en) Pyridine and pyrimidine derivatives as mglur2 antagonists
AP2012006204A0 (en) Indazole and pyrazolopyridine compounds as CCR1 receptor antagonists.
ZA201103462B (en) Aryl piperazine and their use as alpha2c antagonists
IL215483A0 (en) Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
IL205749A0 (en) Modified il-4 mutein receptor antagonists
IL190902A0 (en) Piperazine derivatives useful as ccr5 antagonists
IL217920A0 (en) 5-(3,4-dichloro-phenyl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-ethoxy)-nico tinamide and salts thereof as hdl cholesterol raising agents
AP3583A (en) Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
IL205455A0 (en) 4 - [4 - (2 - adamantylcarbamoyl) - 5 tert - butyl - pyrazol - 1 - yl] benzoic acid - 465
ZA201002171B (en) 2-s-benzyl substituted pyrimidines as crth2 antagonists
IL207700A0 (en) 3-aminoalkyl-1,4-diazepan-2-one melanocortin -5 receptor antagonists
IL190010A0 (en) 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)
SI1710240T1 (sl) Derivati piperazina in njihova uporaba kot zaviralci ponovnega vnosa serotonina ali kot antagonistinevrokinina
SI2155717T1 (sl) 2-(4-(pirazol-4-ilalkil)piperazin-1-il)-3-fenil pirazini in piridini ter 3-(4(pirazol-4-ilalkil)piperazin-1-il)-2-fenil piridini kot antagonisti 5-ht7 receptorja